Key Takeaways
- A 2025 network meta-analysis in BMJ Medicine found tirzepatide 15 mg produced the greatest average weight loss among non-diabetic adults—roughly 20% of body weight—compared to lower reductions with semaglutide 2.4 mg.
- A systematic review in Annals of Internal Medicine confirmed that GLP-1 and dual incretin drugs consistently outperform placebo for weight loss in adults without diabetes, but individual results vary considerably.
- Research published in Diabetes, Obesity & Metabolism identifies early weight loss in the first 4–12 weeks as one of the stronger predictors of whether a patient will be a meaningful responder long-term.
- A real-world study in Chinese adults without diabetes found tirzepatide produced greater weight reduction than semaglutide at comparable time points, consistent with randomized trial data.
- No tool yet reliably predicts who will respond before treatment starts, making early monitoring and dose optimization the main practical strategy available to clinicians.
What do average GLP-1 response rates look like across clinical trials?
GLP-1 response rates across clinical trials vary by drug and dose, but the headline finding is consistent: most people lose a meaningful amount of weight, and the newer medications produce larger average losses than older ones.
Across randomized controlled trials in adults with overweight or obesity who did not have diabetes, semaglutide 2.4 mg (the dose used for weight loss) produced average body weight reductions of roughly 15–17% over about 68 weeks, while tirzepatide — which targets two gut hormone receptors instead of one — produced average losses closer to 20–22% at its highest doses, according to a network meta-analysis comparing GLP-1-based drugs head to head. A systematic review and network meta-analysis of liraglutide, semaglutide, and tirzepatide confirmed that tirzepatide produced the largest average weight loss across the three drugs, with liraglutide — an older GLP-1 medication — producing more modest results, typically around 5–8% body weight reduction.
Those are averages. Averages hide a wide spread.
A review focused specifically on responders and non-responders found that a meaningful share of people on GLP-1 or GLP-1/GIP receptor agonists lose far more than the trial average, while others lose very little. Researchers define a “non-responder” (someone whose body does not react as expected to the medication) differently across studies, but the pattern is consistent: individual results can fall well above or well below the number you see in a headline.
Here is how the average weight-loss figures compare across the three most studied drugs:
| Medication | Receptor targets | Average weight loss in trials |
|---|---|---|
| Liraglutide 3 mg | GLP-1 | ~5–8% body weight |
| Semaglutide 2.4 mg | GLP-1 | ~15–17% body weight |
| Tirzepatide (10–15 mg) | GLP-1 + GIP | ~20–22% body weight |
Sources: network meta-analysis, systematic review
Real-world data adds another layer. A real-world observational study in Chinese adults with obesity found that both semaglutide and tirzepatide produced clinically meaningful weight loss outside of controlled trial conditions, though the absolute numbers were somewhat lower than trial averages — a common pattern when medications move from tightly controlled research settings into everyday clinical use.
One more number worth keeping in mind: an updated systematic review of GLP-1 receptor agonists and co-agonists for weight loss found that weight regain after stopping medication is well-documented across drugs, which means the trial figures reflect results during active treatment, not permanent outcomes.
This content is for general informational purposes only and is not medical advice. Talk to a qualified healthcare professional before starting, changing, or stopping any medication.
How does tirzepatide compare to semaglutide for weight loss outcomes?
Both tirzepatide and semaglutide produce meaningful weight loss. Clinical evidence consistently shows tirzepatide leads to greater average weight reduction—though individual results vary, and neither drug works the same way for everyone.
Tirzepatide targets two gut hormones: GLP-1 (glucagon-like peptide-1, which slows digestion and reduces appetite) and GIP (glucose-dependent insulinotropic polypeptide, which affects how the body stores fat). Semaglutide targets GLP-1 only. That dual action appears to drive the difference in outcomes seen across multiple studies.
A network meta-analysis comparing GLP-1-based drugs for weight loss in adults without diabetes found tirzepatide at its highest studied dose produced roughly 20% body weight reduction, while semaglutide at its highest studied dose produced roughly 15%—a meaningful gap when you translate those percentages into actual pounds for most people (BMJ network meta-analysis). A separate systematic review reached a similar conclusion, placing tirzepatide above semaglutide on average weight loss across the trials reviewed (systematic review, updated).
Real-world data adds texture to those trial numbers. A study in Chinese adults with obesity found tirzepatide users lost more weight than semaglutide users over the observation period, and a higher share of tirzepatide users hit the 10% and 15% weight-loss thresholds (real-world observational study). A network meta-analysis focused on efficacy and safety across liraglutide, semaglutide, and tirzepatide confirmed tirzepatide’s edge on weight outcomes while noting that side-effect profiles—mainly nausea, vomiting, and diarrhea—are broadly similar between the two drugs (efficacy and safety meta-analysis).
Three things matter as you read those numbers:
Averages hide a wide range. Some people lose far more than the study average; others lose less. Research on who responds to each drug is still developing, and no test can reliably predict your outcome in advance (responder prediction review).
Dose matters. Both drugs start low and increase gradually to reduce side effects. The highest weight-loss numbers in trials reflect the highest doses studied, which not everyone reaches or tolerates.
Access and cost differ. Semaglutide has been available longer and may be easier to obtain depending on your insurance and location.
A prescribing clinician can weigh your health history, any other conditions you have, and your tolerance for side effects to help you decide which option makes sense for you.
This content is for general informational purposes only and is not medical advice. It does not replace a conversation with a qualified healthcare professional. Do not make changes to your medication based on this information.
What predicts whether someone will respond to a GLP-1 medication?
No single factor perfectly predicts GLP-1 response rates, but researchers have identified several patterns that make a meaningful difference in who loses the most weight — and who loses very little.
Early weight loss is the clearest signal. A 2025 review of responders vs. non-responders found that people who lose at least 5% of their body weight in the first 12–16 weeks of treatment are far more likely to reach clinically meaningful weight loss targets by the end of a trial. People who don’t hit that early threshold rarely catch up later, even at higher doses. That makes the first few months a useful window for you and your doctor to assess whether a medication is working.
Baseline biology matters, though not in ways you can easily change. The same review identified several factors linked to stronger responses: lower fasting insulin levels before starting treatment, better preserved beta-cell function (beta cells are the cells in your pancreas that make insulin), higher baseline body weight — people with more weight to lose tend to show larger absolute losses, though percentage losses vary — and absence of type 2 diabetes. People without diabetes consistently lose more weight on GLP-1 medications than people with diabetes, a pattern confirmed across multiple systematic reviews.
Genetics play a role too. Variations in the GLP-1 receptor gene — the docking site these medications attach to — appear to influence how strongly someone responds, according to the responder analysis. Genetic testing for this isn’t standard clinical practice yet, so it remains a research finding rather than something you can act on today.
The medication itself matters. A network meta-analysis of GLP-1 based drugs found that tirzepatide, which targets two hormone receptors instead of one, produced greater average weight loss than semaglutide in people without diabetes. Switching medications is worth discussing with your doctor if early response is poor.
Lifestyle factors shape outcomes too. The responder review found that people who combined medication with consistent dietary changes lost significantly more weight than those who relied on the drug alone. Sleep quality and physical activity levels also appeared in the data as modifying factors, though their independent contribution is harder to separate from overall adherence.
Non-response at 12 weeks on a stable dose is a real clinical signal, not a reason to simply wait longer.
This content is for general informational purposes only and is not medical advice. Talk to a qualified healthcare professional before making any decisions about your treatment.
Why do some people lose far less weight than the trial averages?
Some people on GLP-1 medications see far smaller weight losses than trial averages because individual GLP-1 response rates vary widely, shaped by genetics, biology, and behavior — and the averages reported in trials mask that full range. Knowing why can help you set realistic expectations and work more productively with your care team.
Clinical trials report mean weight loss, which sits in the middle of a wide spread. In the semaglutide trials, participants lost anywhere from almost nothing to well above the headline figure. A 2025 systematic review found that roughly 10–15% of people on GLP-1 medications are classified as non-responders — meaning they lose less than 5% of their body weight despite taking the medication as prescribed.
Several factors drive that gap:
Genetics. Variants in the GLP-1 receptor gene change how strongly the drug binds and signals. A 2025 analysis of responders vs. non-responders identified specific genetic profiles associated with blunted weight loss, independent of dose or adherence.
Starting metabolic state. People with insulin resistance, higher baseline insulin levels, or certain hormonal conditions lose weight more slowly. The same responder analysis found that metabolic markers at baseline predicted response better than body weight alone.
Dose reached. Trials report outcomes at the maximum approved dose. Many people in real-world settings never reach that dose because of side effects. A real-world observational study found meaningful differences in weight loss between people who reached full dose and those who stayed at lower doses.
Diet and activity. GLP-1 medications reduce appetite, but they don’t override a diet high in ultra-processed foods. The drug changes hunger signals; food choices still matter.
Gut absorption differences. Individual variation in how quickly the stomach empties affects how much drug reaches circulation at the right time.
The trial average is one point on a bell curve. Some people land well above it. Some land well below. A network meta-analysis comparing multiple GLP-1 drugs confirmed that even within the same medication, the range of individual outcomes is large enough that two people on identical doses can have very different results after a year.
If your results feel disappointing after several months at a stable dose, talk to your prescriber — don’t stop taking the medication. Switching medications, adjusting dose timing, or investigating underlying metabolic factors can all shift the outcome.
This content is for general informational purposes only and is not medical advice. It does not replace consultation with a qualified healthcare professional. Never start, stop, or change a medication based on information you read here.
Does the day you inject semaglutide or tirzepatide affect how well it works?
The day you inject semaglutide or tirzepatide does not change how the medication works in your body — GLP-1 response rates stay consistent regardless of which day of the week you choose. A systematic literature review on injection timing found no clinical evidence that Monday injections outperform Friday injections, or that any particular day produces better weight loss or fewer side effects.
What actually drives how well these medications work is consistency. Both semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are designed to be injected once a week. The drugs build up to a steady level in your bloodstream over time — a concept called steady-state concentration. Missing doses or injecting at irregular intervals disrupts that steady level far more than which day you pick. The timing review confirmed that adherence to a regular weekly schedule is the scheduling factor with real clinical weight.
Pick a day you can stick to. That might be Sunday evening because you’re home, or Wednesday morning because it fits your routine. The right day is the one you’ll actually remember. Some people tie their injection to a recurring weekly event — a grocery run, a gym session — so it becomes automatic.
Side effects don’t cluster around specific days either. Nausea and other GI symptoms are most common when you first start or when your dose increases, not because of the day of the week. The timing review found no evidence linking injection day to side effect severity or frequency.
Individual response varies, but not because of scheduling. Some people lose more weight than others on the same medication and dose. A review on predicting GLP-1 response points to factors like baseline body weight, metabolic health, and genetics — none of which are affected by whether you inject on a Tuesday or a Saturday.
If you travel across time zones regularly, pick a day-of-week anchor rather than a clock-time anchor. Semaglutide and tirzepatide are weekly medications, so a shift of a few hours on any given week is not a problem. What you want to avoid is accidentally doubling up or skipping a full week.
This content is for general informational purposes only and is not medical advice. Talk to your doctor, pharmacist, or another qualified healthcare professional before making any decisions about your medication schedule or treatment.
FAQ
What are typical GLP-1 response rates in people without diabetes?
GLP-1 response rates in non-diabetic adults range from roughly 5% to over 20% body weight loss depending on the drug and dose, based on a 2025 network meta-analysis in BMJ Medicine (PMID 42688617). Placebo-adjusted differences are substantial, but a meaningful minority of participants lose less than 5% of body weight even at maximum doses.
Which GLP-1 medication produces the most weight loss on average?
Tirzepatide 15 mg showed the largest average weight reduction in multiple analyses, including a network meta-analysis (PMID 42688617) and a systematic review in Annals of Internal Medicine (PMID 42673585). Semaglutide 2.4 mg also outperforms older GLP-1 drugs like liraglutide, but by a smaller margin than tirzepatide.
Can doctors predict in advance who will respond to a GLP-1 drug?
No reliable pre-treatment predictor exists yet. Research in Diabetes, Obesity & Metabolism (PMID 42634284) found that early weight loss—typically measured at 4 to 12 weeks—is currently the most practical signal clinicians use to gauge likely long-term response.
What counts as a ‘non-responder’ on a GLP-1 medication?
Definitions vary across studies, but losing less than 5% of body weight after reaching a therapeutic dose for several months is commonly used as a non-response threshold. PMID 42634284 reviews several proposed criteria and notes that dose, adherence, and duration all affect whether someone is truly a non-responder versus undertreated.
Does it matter which day of the week you take semaglutide or tirzepatide?
A 2025 systematic review in Medicina (PMID 42654433) found no clinical evidence that the specific day of the week affects efficacy or tolerability for either drug. Consistency—taking the injection on the same day each week—matters more than which day is chosen.
Are GLP-1 response rates different in real-world patients versus clinical trials?
Real-world data tend to show somewhat smaller average losses than randomized trials, partly because trial participants are more closely monitored and dose-escalated on schedule. A real-world study in Chinese adults without diabetes (PMID 42610030) still found tirzepatide outperforming semaglutide, consistent with trial findings, though absolute losses were variable.
Do newer dual-receptor drugs like tirzepatide work differently from standard GLP-1 drugs?
Tirzepatide targets both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, while semaglutide targets only the GLP-1 receptor. A review in Hormone and Metabolic Research (PMID 42697206) explains that this dual mechanism appears to produce additive effects on appetite suppression and energy expenditure, which may explain the larger average weight losses seen with tirzepatide.
Is it safe to stay on a GLP-1 medication if you are not losing much weight?
That decision depends on your individual health profile and should be made with a qualified healthcare provider. Some patients with modest weight loss still see improvements in blood sugar, blood pressure, or other metabolic markers that may justify continued use.
This article is for general information and is not medical advice. GLP-1 medications are prescription drugs that require clinical supervision — talk to a licensed healthcare provider before starting, stopping, or changing any treatment.